Reuters reveals Singapore’s Temasek considers sale of Advanced MedTech, likely valued at about $1 bln

HomeFinancial

Reuters reveals Singapore’s Temasek considers sale of Advanced MedTech, likely valued at about $1 bln

Reuters has recently reported that Singapore’s investment firm Temasek Holdings is exploring the potential sale of healthcare equipment provider Advan

Reuters reveals Temasek’s PSA considers multi-billion dollar exit from Hutchison Ports
Reuters reveals at least $1 billion of client funds missing at failed crypto firm FTX
Reuters reveals Air India nears historic order for up to 500 jets

Reuters has recently reported that Singapore’s investment firm Temasek Holdings is exploring the potential sale of healthcare equipment provider Advanced MedTech. Reports indicate that the medical technology firm could be valued at over $1 billion in such a sale.

Temasek, a Singaporean sovereign wealth fund, holds a stake of around 40 percent in Advanced MedTech, with the company’s primary investors also holding sizable interests in the medical firm. Advanced MedTech specializes in medical products and services, and covers a range of healthcare-related areas such as medical equipment, diagnostics and digital health.

The potential sale of Advanced MedTech could net Temasek a healthy return on its investment, according to analysts. The company was valued at about $400 million in 2017 and was recently projected to exceed $1 billion. Sources close to the sale assert that Chinese investors are showing keen interest in acquiring the healthcare firm.

However, a deal is far from being finalized as Temasek has yet to make a final decision on whether to go through with the sale. If a divestment does occur, it will mark the fourth acquisition of a healthcare or life sciences firm by a Chinese organization or individual this year.

In the past several years, Chinese firms have invested heavily in medical technology and healthcare in order to capitalize on the massive potential of these sectors. As the demand for high-quality medical services increases in the country, investors have found success in buying and developing healthcare-related firms.

If a sale of Advanced MedTech is ultimately decided, it could be yet another example of Chinese investment leading to profitable returns.

Reuters reveals Singapore’s Temasek considers sale of Advanced MedTech, likely valued at about $1 bln.

Temasek, based in Singapore, is mulling a possible sale of Advanced MedTech, a majority stakeholder in their business, which is likely to fetch a value of around $1 billion.

This comes from Reuters and has been reported by three independent sources who remain anonymous. It is unknown when the potential sale may take place, or to whom it would be made; though some potential buyers are likely to be European and US medical device firms.

Advanced MedTech is up for a re-evaluation by Temasek, who is undertaking a review of their portfolio in light of the current global economic climate. The COVID-19 pandemic has caused an unknown level of disruption to the majority of the world’s markets, and so it is not unexpected for them to redirect their investments into other areas.

What Advanced MedTech Does

Advanced MedTech specializes in innovative medical devices, manufactured to support health and wellbeing, sport, and lifestyle applications. Founded in 1991 and based in Switzerland, they are a global leader in the medical device industry and pioneering in their own right.

Advanced MedTech’s Leadership

Advanced MedTech is managed by a respected management team, underpinned by the leadership of its CEO, Peter Buhl. Peter has over two decades of experience within the medical device industry, and has been credited with expanding the company’s reach and revenue significantly.

Under his leadership, Advanced MedTech has grown to become a leader in their field, with a presence in over 150 countries, supported by 25 subsidiaries and four research hubs, which has resulted in them becoming one of the world’s largest medical device companies.

Advanced MedTech’s Financials

Advanced MedTech is a profit-making business, and their financial reports have been impressive. Over the past eighteen months, their sales have been on the rise, reaching over $1 billion in 2019. They also have a healthy balance sheet, with positive cash flow and assets valued at over $3 billion.

Conclusion

In conclusion, Temasek is currently considering the potential sale of Advanced MedTech, which they likely value at around $1 billion. Advanced MedTech is a profitable and well-managed business, with many years of experience in the medical device industry, making them an attractive prospect for potential buyers.

COMMENTS

WORDPRESS: 0
    DISQUS: